1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDiscovery Program is sponsored by California Institute for Regenerative Medicine (CIRM). Supports early-stage basic research that advances the understanding of how genetic therapies work and explores groundbreaking treatments and technologies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Discovery Stage Research – CIRM DISC4 Awards: Supporting Multidisciplinary, Collaborative Research [Now Closed] DISC4 supports expansive, cross-disciplinary, and integrated studies led by large collaborative teams that apply a range of technologies and approaches to accelerate foundational insights into understanding human diseases.
Download the DISC4 Program Announcement (PA) for more details regarding award eligibility, review criteria, and application information. DISC4: Program Announcement [PDF | Updated April 15, 2026] Important: All prospective DISC4 applicants must first complete a pre-submission form. Visit the DISC4 Awards page for more information about the DISC4 awards, including deadlines, requirements, and FAQs.
DISC5 Awards: Funding Opportunity for Discovery Stage Research [Now Closed] Visit the DISC5 Awards page on our website for more information about the DISC5 Awards, including deadlines, requirements, webinar information, and FAQs.
The DISC5 awards support exploratory and innovative foundational research led by pairs of investigators applying a range of technologies and approaches to address knowledge gaps or bottlenecks in stem cell biology or regenerative medicine.
Download the DISC5 Program Announcement (PA) for more details regarding award eligibility, review criteria, and application information: DISC5: Program Announcement Multidisciplinary collaborations Disease biology insights to facilitate novel target/biomarker identification Basic stem cell biology Innovations in stem-cell based technologies Bottlenecks in regenerative medicine Immune-Tissue Interplay in Disease, Homeostasis, and Repair (FY 2026/2027) No disease area or organ system focus area 5 or more CA investigators; Multi-institutional Annually, June (pre-submission) To Submit an Application: 1.
Go to the Grants Management Portal 2. After logging in, click on the Menu tab Select the tab labeled “Open Programs” under the section labeled “RFAs and Programs Open for Applications,” click on the “ Start a Grant Application ” link for your selected program. 3.
Complete each section of the Application Click on the appropriate link and follow the posted instructions. Proposal templates can be located and submitted under the “ Uploads ” section. 4.
To submit your Application Click on the “ Done with Application ” button. The “ Done with Application ” button will be enabled when all the mandatory sections have been completed. Please note that once this has been selected, you will no longer be able to make changes to your application.
5. To confirm submission of your Application Select the tab labeled “ Your Applications ” and check the table under the section labeled “ Your Submitted Applications. ” You will see your application number and project title listed once the submission process has been completed.
According to the current listing, eligibility includes: Not explicitly detailed, but generally targets researchers and institutions focused on regenerative medicine and genetic therapies. Confirm the full requirements in the official notice before applying.
Discovery Program is funded by California Institute for Regenerative Medicine (CIRM). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Preclinical Development (PDEV) program is sponsored by California Institute for Regenerative Medicine (CIRM). The PDEV program supports preclinical development of stem cell-based and genetic therapies that offer potential for transformative clinical impact and address current barriers to patient access. This includes research on stem cell-derived retinal pigment epithelium (RPE) cells for treating maculopathies and supporting photoreceptors.
CLIN2 Awards: Funding Opportunity for Clinical Trials is sponsored by California Institute for Regenerative Medicine (CIRM). CIRM's CLIN2 Awards program supports the clinical development of stem cell-based and genetic therapy approaches for treating diseases with unmet medical needs. The program aims to expedite clinical development towards late-stage trials through innovative trial designs and strategies for market access and pre-commercialization.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
NIA Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). The NIA SBIR/STTR programs support small businesses in developing technologies for aging-related health issues, including AI-driven drug discovery tools and assistive technologies for older adults aging in place. These programs aim to help small businesses develop effective treatments and interventions for healthy aging.
DARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleThe FY2026 MEP Center State Competition ran in two rounds: eight states worth $139.1 million, then fourteen more worth $232.4 million, both closing August 21, 2026. That's 43 percent of the national network recompeted in twelve months, under a 50 percent non-federal cost share, while the administration's own budget request proposed eliminating the program. Here's what the award tables reveal, why incumbents are genuinely at risk, and how to position for the FY2027 wave.
Read articleOn August 14, 2026, the California Arts Council approved nearly $24.6 million across 1,200 grant awards. Buried in the release is a rare thing: before-and-after data showing exactly how much the ranked-priority bonus moved the pool. Small organizations went from 53% of applicants to 72% of awardees. Geography moved 19 points. First-time status barely moved at all. Here is what that means for the 2027 cycle.
Read article